SCHEMBL29954503

SCHEMBL29954503

O=Cc1cccc(O)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 8/20 0.61
TRIM24 O15164 1/20 0.60
TRIM33 Q9UPN9 1/20 0.60
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
TSHR P16473 2/20 0.50
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
LMNA P02545 1/20 0.46
THRB P10828 1/20 0.46
BLM P54132 1/20 0.46
TLR2 O60603 1/20 0.42
TLR1 Q15399 1/20 0.42
TLR6 Q9Y2C9 1/20 0.42
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286523 1.00 ERN1 (0.61) ERN1TRIM24TRIM33CA1CA2
SCHEMBL3794351 0.83 TDP1 (0.58) ERN1TRIM24TRIM33CA1CA2
SCHEMBL16956921 0.79 TSHR (0.52) ERN1TRIM24TRIM33CA1CA2
SCHEMBL219677 0.79 ERN1 (0.54) ERN1TRIM24TRIM33MEN1KMT2A
SCHEMBL31300223 0.79 ERN1 (0.54) ERN1TRIM24TRIM33MEN1KMT2A
SCHEMBL6559485 0.77 TSHR (0.50) ERN1TRIM24TRIM33CA1CA2
SCHEMBL95211 0.76 ALDH1A1 (0.54) ERN1TRIM24TRIM33TSHRMEN1
SCHEMBL6048616 0.76 ERN1 (0.67) ERN1TRIM24TRIM33CA1CA2
SCHEMBL29407137 0.76 ERN1 (1.00) ERN1TRIM24TRIM33CA1CA2
SCHEMBL30011286 0.76 ALDH1A1 (0.54) ERN1TRIM24TRIM33TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS LILLY CO ELI (US) 2025-11-20 US disclosed
EP-4648762-A2 PPARG MODULATORS University of Florida Research Foundation, Incorporated (US) 2025-11-19 EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 EP disclosed
US-12404298-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2025-09-02 US disclosed
WO-2025107036-A1 DUAL INHIBITORS OF AMINE OXIDASES AND PEROXIDASES, AND USES THEREOF SYNTARA LIMITED (AU) 2025-05-30 WO disclosed
CN-119528956-B BODIPY light-cage chemiluminescent molecule, nano microsphere, and synthesis method and application thereof 中南林业科技大学 2025-05-13 CN disclosed
CN-119528956-A BODIPY light-cage chemiluminescent molecule, nano microsphere, and synthesis method and application thereof 中南林业科技大学 2025-02-28 CN disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 WO disclosed
WO-2024151519-A2 PPARG MODULATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) 2024-07-18 WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 WO disclosed
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 US disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 US disclosed
EP-4157821-A1 SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 Constellation Pharmaceuticals, Inc. (US) 2023-04-05 EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20220324904-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2022-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404298-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R ERN1 1650/4885TRIM24 2673/4885TRIM33 1304/4885
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R ERN1 1650/4885TRIM24 2673/4885TRIM33 1304/4885
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R ERN1 1650/4885TRIM24 2673/4885TRIM33 1304/4885
US-11787834-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R ERN1 1650/4885TRIM24 2673/4885TRIM33 1304/4885
US-20220324904-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R ERN1 1650/4885TRIM24 2673/4885TRIM33 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.